Analyst Price Targets — TWST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 10:43 am | Luke Sergott | Barclays | $55.00 | $50.38 | TheFly | Twist Bioscience price target raised to $55 from $50 at Barclays |
| February 3, 2026 3:06 pm | — | Robert W. Baird | $50.00 | $47.73 | TheFly | Twist Bioscience price target raised to $50 from $33 at Baird |
| February 3, 2026 12:59 pm | — | Evercore ISI | $52.00 | $47.42 | TheFly | Twist Bioscience price target raised to $52 from $42 at Evercore ISI |
| February 3, 2026 10:29 am | — | Barclays | $50.00 | $46.81 | TheFly | Twist Bioscience price target raised to $50 from $39 at Barclays |
| January 5, 2026 2:57 pm | — | Evercore ISI | $42.00 | $34.35 | TheFly | Twist Bioscience price target raised to $42 from $34 at Evercore ISI |
| December 15, 2025 10:57 am | — | Barclays | $39.00 | $30.94 | TheFly | Twist Bioscience price target raised to $39 from $37 at Barclays |
| November 3, 2025 9:30 pm | Steven Etoch | Stephens | $41.00 | $31.57 | TheFly | Twist Bioscience initiated with an Overweight at Stephens |
| October 2, 2025 10:44 am | — | Barclays | $40.00 | $29.26 | TheFly | Twist Bioscience price target lowered to $40 from $45 at Barclays |
| August 4, 2025 5:10 pm | — | Evercore ISI | $46.00 | $30.21 | TheFly | Twist Bioscience price target lowered to $46 from $50 at Evercore ISI |
| May 6, 2025 11:28 am | Catherine Ramsey Schulte | Robert W. Baird | $44.00 | $32.75 | TheFly | Twist Bioscience price target lowered to $44 from $54 at Baird |
Latest News for TWST
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 second quarter ended March 31, 2026, before the opening of the market on May 4, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time…
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) CFO Adam Laponis sold 2,597 shares of the company's stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $49.89, for a total value of $129,564.33. Following the completion of the transaction, the chief financial officer directly owned
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) Director Melissa Starovasnik sold 1,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total transaction of $51,000.00. Following the completion of the transaction, the director directly owned 25,722 shares in the
SG Americas Securities LLC lifted its holdings in Twist Bioscience Corporation (NASDAQ: TWST) by 350.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 76,484 shares of the company's stock after acquiring an additional 59,500 shares during the quarter. SG Americas Securities LLC
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month target price
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TWST.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.